ライフサイエンスコーパス: topical steroid

1 ntraocular inflammation that resolved with a topical steroid.

2 D participants who filled prescriptions for topical steroids.

3 therapies and were generally manageable with topical steroids.

4 oNV that had not responded to treatment with topical steroids.

5 dietary restriction and those that received topical steroids.

6 pical antibiotics, and 98% were treated with topical steroids.

7 dalities or have undesired side effects from topical steroids.

8 nflammatory drugs are minimizing the role of topical steroids.

9 oral steroids 1.5 (1.0-2.4), "super potent" topical steroids 1.2 (0.8-1.8) , "low potency" topical s

10 und-associated group were more likely to use topical steroids (20/22 [91%] vs 17/27 [63%]; P = 0.024)

11 ng with topical and systemic antibiotics and topical steroids (221 children), and one to no specific

12 olved following both dietary restriction and topical steroids (3/17 and 5/9 patients respectively, P

13 Neither an antibiotic nor a topical steroid alone or in combination was effective as

14 rneal findings, resolution was achieved with topical steroids and lubrication, whereas some patients

15 ll patients had failed previous therapy with topical steroids and methotrexate and/or cyclosporine.

16 ers completely resolved after treatment with topical steroids and oral doxycycline.

17 Topical steroids and oral nonsteroidal anti-inflammatory

18 Mild scleritis/limbitis responsive to topical steroids and oral NSAIDs was present in 11 of 36

19 All patients were managed with frequent topical steroids and were followed closely for signs of

20 kept under observation, with the addition of topical steroids and/or cycloplegics in eyes that demons

21 ncluded use of skin moisturizers, sunscreen, topical steroid, and doxycycline.

22 , including topical prostaglandin analogues, topical steroids, and argon laser trabeculoplasty.

23 shed new light on the mechanism of action of topical steroids, and demonstrates the critical role of

24 Medicare and patient out-of-pocket costs for topical steroids, and to model potential savings that co

25 Although topical steroids are among the most commonly prescribed

26 Topical steroids are frequently used to control corneal

27 ding sound advice and easing fears regarding topical steroids, as well as pursuing conservative treat

28 Medicare Part D expenditures on topical steroids between 2011 and 2015 were $2.3 billion

29 Dietary restriction alone, similar to topical steroids, can reverse fibrosis in children with

30 Although topical steroids continue to be a mainstay of therapy, n

31 Clinical symptoms of epiphora settled with topical steroid drops, but the clinical signs of chronic

32 Apart from the topical steroids during the first week, medical treatmen

33 To compare standard and frequent topical steroids for postsurgical macular edema (ME).

34 oral suspension (BOS), a novel muco-adherent topical steroid formulation, to reduce symptoms and esop

35 substitution of the most affordable generic topical steroid from the corresponding potency class may

36 uld result from substitution of the cheapest topical steroid from the corresponding potency class.

37 In addition, there is limited evidence that topical steroids improve the sense of smell, especially

38 erved in 6 eyes (7.5%) and was reversed with topical steroids in all cases.

39 that topical NSAIDs are more effective than topical steroids in preventing PCME.

40 any DSEK patients are maintained on low-dose topical steroids indefinitely.

41 maintaining adequate amebicidal therapy if a topical steroid is used in the management of Acanthamoeb

42 be reasonably supported, whereas the use of topical steroids is unlikely to be beneficial.

43 Anti-inflammatory drugs such as topical steroids may be beneficial but are underresearch

44 Topical steroids might reduce stomatitis incidence and s

45 have the potential to reduce the quantity of topical steroids necessary to keep disease quiescent.

46 Treatment requires moderately potent topical steroid ointments.

47 pical steroids were compared to those taking topical steroids only.

48 pical steroids 1.2 (0.8-1.8) , "low potency" topical steroids OR 1.1 (0.7-1.6); pimecrolimus 0.8(0.4-

49 Treatment is based on systemic or topical steroids or identification and elimination of fo

50 Anecdotal use of topical steroid oral prophylaxis has been reported in pa

51 Patients' out-of-pocket spending for topical steroids over the same period was $333.7 million

52 resolution of inflammation, with or without topical steroids, over the course of a few months.

53 tacrolimus OR 0.8 (0.4-1.7), and concomitant topical steroids, pimecrolimus, and tacrolimus 1.0 (0.3-

54 IOL at the time of surgery and received only topical steroids postoperatively.

55 Most topical steroids prescribed were generic drugs.

56 ive therapies, most commonly due to fears of topical steroid side-effects and dissatisfaction with co

57 se in Medicare and out-of-pocket spending on topical steroids that is driven by higher costs for gene

58 Concerning topical steroids, the most frequently instructed item wa

59 With topical steroid therapy 5 times per day during the first

60 e may be treated effectively with aggressive topical steroid therapy and lubrication.

61 Early intensified postoperative topical steroid therapy constitutes an effective prophyl

62 proliferation in the pancreatic LN, although topical steroid therapy did not enhance this.

63 ill patients; use of genetic techniques and topical steroid therapy in treating graft-versus-host di

64 With hourly topical steroid therapy none of the patients developed C

65 Patients with CoNV unresponsive to topical steroid therapy.

66 om 12 patients (23%) had previous failure to topical steroid therapy.

67 ival injection, or hypopyon, and responds to topical steroid therapy.

68 dle (MN) delivery system and combine it with topical steroid to minimise local inflammation and promo

69 of whether a child's AD required the use of topical steroids, topical calcineurin inhibitors, or oth

70 wer adverse-effect profile than conventional topical steroid treatments or other medical or surgical

71 Topical steroid use (37/49 [76%]) was the most common as

72 idal anti-inflammatory drug (NSAID) added to topical steroid use after uncomplicated phacoemulsificat

73 Topical vancomycin use, topical steroid use, and contact lens wear did not incre

74 1%) underwent cataract extraction related to topical steroid use.

75 Increasing frequency of use of swallowed topical steroids was associated with a lower risk for bo

76 ssociated with graft rejection, cessation of topical steroids was most significant.

77 tion of topical NSAIDs filled in addition to topical steroids were compared to those taking topical s

78 trials published from 1996 onward comparing topical steroids with topical NSAIDs in controlling infl

79 nt savings from substitution of the cheapest topical steroid within the corresponding potency class w